Thursday, October 28, 2021 1:13:08 PM
Our current phase of brine creation has focused on roasting with chloride salt use and distilled water use only in creating a very low impurity solution with a neutral to slightly basic pH solution. As such, early results show a potentially low capex, low environmental, and low carbon footprint for producing lithium carbonate.
The below table shows high-acid and non-acid solution ranges that will make up some of the first phase solutions now being prepared for shipping to the DOE in the nanotechnology Direct Lithium Exchange process (DLE) process:
Solution Type
PPM B
PPM Ca
PPM K
PPM Mg
PPM Na
PPM Li
Li/Mg Ratio
% Li into solution
High Acid pH 1.0
35
3,200
1,100
1,370
500
101
1/13.5
77.0
Non-Acid pH 6.8
BD
80
200
7
300
14
2.01/1
31.3
Note: BD is below the detection limit of 5 ppm. High acid solution ratio 1 part claystone to 9 parts high acid for 60min at 50c. Non-Acid solution 1 part roasted claystone 60min at 810c to 29 parts non-acid solution for 60min at 60c.
DLE uses different mediums of exchange to capture lithium ions while allowing other contaminant ions to pass by allowing for high purity capture of the lithium ions. We are providing a wide assortment of synthetic brine solutions to see how nanotechnology will handle the recovery of lithium ions. Many factors are involved in the ultimate economic recovery of lithium such as grade, recovery, reagent costs, energy costs, CO2 input costs.
One of the biggest benefits of lithium-hosted claystone deposits is the ability to make the lithium enriched solutions work with the DLE process. Resulting in the best possible economic and environmentally friendly recovery process possible in this rapidly expanding field.
"We have bookmarked the two ends of the spectrum to be used in the first series of solution tests, using the technology mentioned above. Throughout this project, and in the coming months, we will provide updates when results warrant," Stated President and CEO Robert McAllister."
History.htm
Recent ENRT News
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/01/2024 06:21:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 03:41:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/11/2024 08:38:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/29/2023 06:24:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 02:01:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 02:02:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 09:09:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2023 10:06:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2023 01:06:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/12/2023 08:29:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 09:24:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM